Transfusion of Lifespan-Extended Neutrophils Restores Immune Defenses in Neutropenic Hosts
Technology Overview
As of today, the main clinical approach to neutropenia is preventing it in risky scenarios using a granulocyte colony-stimulating factor (G-CSF). However, this therapy doesn’t work if bone marrow function is compromised. In addition, G-CSF treatment comes with different important side effects such as bone pain, headache, fatigue, and nausea. An alternative therapeutic option exists–Granulocyte transfusion, also known as neutrophil transfusion or GTX, but its efficacy is controversial and the neutrophils survival and function need to be improved.
Dr. Luo Hongbo’s group at Boston Children’s Hospital improved the efficacy of neutrophil transfusion by prolonging neutrophil survival without compromising their function. By using a combined treatment, caspases/LMP/oxidant/necroptosis inhibition plus G-CSF (CLON-G), the group was able to prolong human and mouse neutrophil half-life in vitro from <1 day to >5 days. Of note, CLON-G-treated aged neutrophils had equivalent morphology and function to fresh neutrophils, with no impairment to critical effector functions including phagocytosis, bacterial killing, chemotaxis, and reactive oxygen species production. More importantly, transfusion with stored CLON-G-treated 3-day-old neutrophils enhanced host defenses, alleviated infection-induced tissue damage, and prolonged survival as effectively as transfusion with fresh neutrophils.
Applications
-
Cancer chemotherapy/ radiation
-
Infections
-
Congenital bone marrow disorders
-
Autoimmune disorders
-
Specific medicines (drug-induced neutropenia)
Advantages
IP Status:
